EOLS · Evolus, Inc. · Stock research

Current Thesis

The margin-inflection leg established by the 2026-08-05 Q2 print is still being paid for. That quarter put net revenue at $84.1M (+21% YoY) against a consensus near $81.6M, adjusted EBITDA at $4.7M (third consecutive positive quarter, a $12.6M YoY swing), and lifted the FY2026 revenue floor to $330–337M from $327–337M. Since the prior note the tape has extended rather than digested: the 2026-08-21 close was $8.39, the 52-week high has been marked up to $8.60, and the three-month price change stands at +37.8% with RSI(14) at 77.3. What an investor is buying here is operating leverage that has now shown up in three prints plus a filler line attaching to an existing 18,000-account toxin base. What has changed since 2026-08-15 is not a company disclosure — it is the calendar. The Section 232 pharmaceutical proclamation carries a 2026-09-29 effective date for smaller manufacturers, and Jeuveau is imported from South Korea.

Bullish and bearish views on Evolus, Inc.

The model's bull view on Evolus, Inc. (EOLS), in brief: Q2 2026 (2026-08-05): net revenue $84.084M, +21% YoY, above the ~$81.6M consensus; FY2026 guidance raised to $330–337M, adjusted gross margin guidance to 67.0–67.5%, non-GAAP opex narrowed to $212–216M. The bear view: The revenue beat carried a wider per-share loss: adjusted EPS -$0.12 versus a -$0.04 consensus on 2026-08-05. Both cases follow in full.

Bull Case

• Q2 2026 (2026-08-05): net revenue $84.084M, +21% YoY, above the ~$81.6M consensus; FY2026 guidance raised to $330–337M, adjusted gross margin guidance to 67.0–67.5%, non-GAAP opex narrowed to $212–216M.
• Adjusted EBITDA $4.7M, a $12.6M improvement on the year-ago quarter — three straight positive quarters. The leverage argument now rests on reported figures.
• 2028 framework reaffirmed on the 2026-08-05 call: $450–500M net revenue, 13–15% adjusted EBITDA margin, international above 15% of revenue.
• Cross-sell is quantified in the Q2 deck: dual-product accounts purchased 2.5x the volume of single-product accounts year-to-date; roughly 600 accounts added in the quarter against a base above 18,000; 270,000+ loyalty redemptions at a ~71% repeat rate.

• South Korea is inside the preferential tier of the Section 232 pharma proclamation — the named jurisdictions are the EU, Japan, South Korea, Switzerland/Liechtenstein and the UK, against a 100% default rate for countries outside those tiers (Clinical Leader summary of the proclamation). The Korea-specific rate is not given in that source and is not asserted here.
• Territory expansion, 2026-08-03/04: the Symatese Aesthetics licence was amended to add Canada, Australia and New Zealand for the full Estyme HA gel line. Terms undisclosed, so no revenue figure attaches to it.
• Sell-side sits well above spot: stockanalysis.com showed a $15.00 average target across 7 analysts as of 2026-08-21, versus the $14.50 aggregate across 6 ratings tracked on 2026-08-11.

Bear Case

• The revenue beat carried a wider per-share loss: adjusted EPS -$0.12 versus a -$0.04 consensus on 2026-08-05. Positive adjusted EBITDA and a deeper adjusted EPS miss printed in the same quarter.
• The guide implies second-half deceleration. FY2026 of $330–337M is 11–13% full-year growth against Q2's +21%.
• Q2's 69% adjusted gross margin included roughly 120bps of tariff refund benefit, and the FY guide of 67.0–67.5% sits below the reported quarter. The margin optics do not repeat mechanically.
• Tariff exposure is now dated, and the company's bucket is undisclosed. Under the proclamation as summarised by Clinical Leader, the applicable rate turns on country of origin, a Commerce-approved onshoring plan and a signed MFN pricing agreement with HHS — 0% with a fully executed agreement, a transitional 20% onshoring rate that escalates to 100% on 2030-04-02, 100% by default. Evolus has made no disclosure locating itself in that structure through 2026-08-21.
• Balance sheet against spend: cash and equivalents of $45.2M at 2026-06-30 versus FY non-GAAP opex guidance of $212–216M, with a $250M Form S-3 universal shelf on file. No prospectus supplement had appeared through 2026-08-21 in the sources reviewed, so the shelf remains unused and available.
• The entry is extended and unresolved for roughly ten weeks. RSI 77.3 at the 2026-08-21 close, -2.4% from the 52-week high, no company-confirmed event before the ~November Q3 print.

Setup & Price Structure

• Last completed daily close 2026-08-21: $8.39, with the 52-week high marked at $8.60. The prior note referenced a 2026-08-14 close of $8.15 against a $8.34 high, so the leg made a higher high in the interim week.
• Three-month price change +37.8% against +25.5% measured on 2026-08-14 — the advance steepened rather than stalled after the print was absorbed.
• RSI(14) 77.3 on 2026-08-21 versus 78.9 on 2026-08-14: a higher price high on a lower momentum reading. Two observations support no conclusion about divergence; it is recorded as an observable, and a third lower reading at a fourth higher high would be the first thing resembling evidence.
• Moving averages as of 2026-08-11: 50-day $6.52, 200-day $5.56. The 2026-08-05 post-print gap zone sits on top of the 50-day reading, which is what makes ~$6.50 the structural floor of this leg rather than an arbitrary retracement.
• Crowding observables: market capitalisation $527.74M and institutional ownership 90.69% as of 2026-08-11; price within 2.4% of a high it set in the same week; a live $250M shelf requiring no new registration; three of the last 30 days' headlines all dated 2026-08-04/05, meaning the news flow driving the tape is now nearly three weeks stale.

Catalyst Calendar (next 30 days)

• 2026-08-23 → 2026-09-22: no company-confirmed Evolus event is scheduled in this window as of 2026-08-21. The stretch is unresolved by design.
• 2026-09-29 — Section 232 pharmaceutical tariff effective date for smaller manufacturers (large companies: 2026-07-31). Determines the landed-cost treatment of Korea-supplied Jeuveau from Q4 onward.
• ~2026-10-30 (est.) — AbbVie Q3 2026 print with Allergan Aesthetics commentary; the read-across on US facial-injectable category volume.
• ~2026-11-04 (est.) — Evolus Q3 2026 results; first test of whether the H2 implied by $330–337M is conservatism or deceleration, and whether the 69% Q2 gross margin held without the tariff refund.
• ~2026-12-31 (est.) — Evolysse Sculpt US approval, guided by management as expected by end of 2026.

What Would Change Our Mind

The structure that defines this leg is the 2026-08-05 print gap sitting on the 50-day average, which read $6.52 on 2026-08-11. Losing that returns the name to its pre-print range and makes the re-rating a one-quarter event: a weekly close below $6.50 is the gradeable break. Three things would break the fundamental case ahead of price. First, an offering — a 424B prospectus supplement or an 8-K announcing common stock or a convertible off the $250M shelf while the shares trade near $8.60, against $45.2M of cash at 2026-06-30. Second, a tariff outcome that puts Korea-supplied Jeuveau outside the preferential tier, or company disclosure placing it at the 20% or 100% rate; the 2026-09-29 date passing with no disclosure at all would leave the exposure unpriced rather than resolved. Third, Q3 revenue growth printing below 11% YoY or adjusted gross margin below 67% without a disclosed offsetting item, either of which would confirm that the 11–13% implied full-year growth is demand, not conservatism. On the other side, the case strengthens on a Q3 print above 15% YoY growth with adjusted gross margin held at or above 67% and an unfunded balance sheet still unfunded.

Correlation Notes

• AbbVie (Allergan Aesthetics / Botox) is the category benchmark; its ~2026-10-30 aesthetics commentary moves Evolus before Evolus reports.
• Revance (RVNC) and Galderma are the direct toxin comparables; a value-tier price war shows up in Evolus gross margin before it shows up in revenue.
• Daewoong Pharmaceutical (KRX) manufactures the Jeuveau drug substance; supply, litigation and Korean regulatory news there flow directly into the US franchise.
• USD/KRW and US pharma trade policy sit upstream of landed cost — the Q2 gross margin already carried a ~120bps tariff refund, so the P&L is demonstrably rate-sensitive.
• Small-cap biotech risk appetite (XBI) and cash-pay discretionary spend: a $527.74M market capitalisation with 90.69% institutional ownership means index-level de-risking and consumer aesthetics demand both hit the tape harder than the fundamentals move.